Weight loss pill could replace injections, would be transformative for millions
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Pharmaceutical Technology2h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
MyJoyOnline20h
The New Weight Loss Drugs and the Role of Dietitians in LMICs
Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...
FierceBiotech3h
Eli Lilly’s next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Parade on MSN7h
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like Ozempic and Wegovy—and consumers are becoming increasingly concerned. While ...
Nature22h
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...